Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Neuroone Medical Technologies (NMTC) Change in Receivables (2020 - 2025)

Neuroone Medical Technologies (NMTC) has disclosed Change in Receivables for 6 consecutive years, with $1.4 million as the latest value for Q4 2025.

  • For the quarter ending Q4 2025, Change in Receivables fell 36.27% year-over-year to $1.4 million, compared with a TTM value of $292954.0 through Dec 2025, down 83.95%, and an annual FY2025 reading of $1.1 million, up 516.05% over the prior year.
  • Change in Receivables was $1.4 million for Q4 2025 at Neuroone Medical Technologies, up from $1.3 million in the prior quarter.
  • Across five years, Change in Receivables topped out at $2.2 million in Q4 2024 and bottomed at -$2.1 million in Q1 2025.
  • Average Change in Receivables over 5 years is $154221.8, with a median of $11956.0 recorded in 2022.
  • The sharpest move saw Change in Receivables skyrocketed 892.25% in 2023, then tumbled 16849.45% in 2025.
  • Year by year, Change in Receivables stood at -$23708.0 in 2021, then soared by 361.86% to $62082.0 in 2022, then skyrocketed by 775.29% to $543399.0 in 2023, then soared by 303.44% to $2.2 million in 2024, then tumbled by 36.27% to $1.4 million in 2025.
  • Business Quant data shows Change in Receivables for NMTC at $1.4 million in Q4 2025, $1.3 million in Q3 2025, and -$318780.0 in Q2 2025.